Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults

Journal of Infectious Diseases

Volumn 203, Issue 12, 2011, Pages 1815-1823

  Crum Cianflone, Nancy F ^a,b   Wilkins, Kenneth ^a   Lee, Andrew W ^c   Grosso, Anthony ^c   Landrum, Michael L ^a,d   Weintrob, Amy ^a,e   Ganesan, Anuradha ^a,e   Maguire, Jason ^a,f   Klopfer, Stephanie ^c   Brandt, Carolyn ^a,b   Bradley, William P ^a   Wallace, Mark R ^g   Agan, Brian K ^a   Banks, Susan ^h   Bavaro, Mary ^h   Chun, Helen ^h   Decker, Cathy ^h   Eggleston, Conner ^h   Fraser, Susan ^h   Hairston, Heather ^h   Hartzell, Joshua ^h   Johnson, Arthur ^h   Kortepeter, Mark ^h   Lalani, Tahaniyat ^h   Lifson, Alan ^h   Linfesty, Michelle ^h   Macalino, Grace ^h   Merritt, Scott ^h   Nagaraj, Barbara ^h   O'Connell, Robert ^h   Okulicz, Jason ^h   Peel, Sheila ^h   Polis, Michael ^h   Powers, John ^h   Tasker, Sybil ^h   Whitman, Timothy ^h   Wortmann, Glenn ^h   Zapor, Michael ^h   more..

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^g Infectious Disease Clinic   (United States)

^h Orlando Regional Medical Clinic ^*

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; BODY MASS; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG RESPONSE; ETHNICITY; FEMALE; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VACCINATION; VIRUS LOAD;

ADULT; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; LINEAR MODELS; MALE; MILITARY PERSONNEL; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 79957518895     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir180     Document Type: Article

References (43)

1. Wallace MR, Hill HE, Tasker SA, Miller LK. Hepatitis A in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27:651-3.
2. Fonquernie L, Meynard JL, Charrois A, Delamare C, Meyohas MC, Frottier J. Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 32:297-9. (Pubitemid 32524803)
3. Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007; 14:189-93.
4. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7. (Pubitemid 32173638)
5. Pol S, Lebray P, Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms. Clin Infect Dis 2004; 38:S65-72.
6. Keeffe E. Hepatitis A in patients with chronic liver disease - severity of illness and prevention with vaccination. J Viral Hepat 2000; 7:15-7. (Pubitemid 30337607)
7. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286-90. (Pubitemid 28065254)
8. Costa-Mattioli M, Allavena C, Poirier AS, Billaudel S, Raffi F, Ferré V. Prolonged hepatitis A infection in an HIV-1 seropositive patient. JMed Virol 2002; 68:7-11. (Pubitemid 34827165)
9. Ida S, Tachikawa N, Nakajima A, et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 2002; 34:379-85. (Pubitemid 34062240)
10. Aberg JA, Kaplan JE, Libman H, et al; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:651-81.
11. Fiore AE, Wasley A, Bell BP; Advisory Committee on Immunization Practices. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-23.
12. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118: S75-83.
13. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171:S44-9.
14. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271:1328-34. (Pubitemid 24132458)
15. Furesz J, Scheifele DW, Palkonyay L. Safety and effectiveness of the new inactivated hepatitis A virus vaccine. Can Med Assoc J 1995; 46:40-2.
16. Levy MJ, Herrera JL, DiPalma JA. Immune globulin and vaccine therapy to prevent hepatitis A infection. Am J Med 1998; 105:416-23. (Pubitemid 28536227)
17. Kemper CA, Haubrich R, Frank I, et al; California Collaborative Treatment Group. Safety and immunogencity of hepatitis A vaccine in human immunodeficiency virus-infected patients: A double-blind, randomized, placebo-controlled trial. J Infect Dis 2003; 187:1327-31. (Pubitemid 36438975)
18. Shire NJ, Welge JA, Sherman KE. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: A hierarchical Bayesian meta-analysis. Vaccine 2006; 24:272-9. (Pubitemid 41790430)
19. Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39:1207-13. (Pubitemid 40169321)
20. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and un-infected homosexual men. J Infect Dis 1997; 176:1064-7. (Pubitemid 27411052)
21. Tilzey AJ, Palmer SJ, Harrington C, O'Doherty MJ. Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 1996; 14:1039-41. (Pubitemid 26281291)
22. Santagostino E, Gringeri A, Rocino A, Zanetti A, de Biasi R, Mannucci PM. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost 1994; 72:508-10. (Pubitemid 24305640)
23. Weinberg A, Gona P, Nachman SA, et al; International Maternal Pediatric Adolescent AIDS Clinical Trials P1008 Team. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006; 193:302-11. (Pubitemid 43113494)
24. Weinberg A, Huang S, Fenton T, et al; International Maternal Pediatric Adolescent AIDS Clinical Trials P1008 Team. Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment. J Acquir Immune Defic Syndr 2009; 52:17-24.
25. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 2005; 19:1702-4. (Pubitemid 41502688)
26. Hess G, Clemens R, Bienzle U, Schönfeld C, Schunck B, Bock HL. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995; 46:40-2.
27. Weintrob AC, Grandits GA, Agan BK, et al; Infectious Diseases Clinical Research Program HIV Working Group. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr 2009; 52:574-80.
28. Ashur Y, Adler R, Rowe M, Shouval D. Comparison of immunogenicity of 2 hepatitis A vaccines - VAQTA and HAVRIX - in young adults. Vaccine 1999; 17:2290-6. (Pubitemid 29225681)
29. Andre FE. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2001; 20:292-3. (Pubitemid 32973767)
30. Centers for Disease Control and Prevention (CDC). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41:961-2.
31. VAQTA hepatitis A vaccine, inactivated [prescribing information]. Whitehouse Station, New Jersey: Merck and Company; 2010. Publication 9987013. http://merck.com/product/usa/pi-circulars/v/vaqta/vaqta-pi.pdf. Accessed 1 June 2010.
32. Wiedermann G, Kundi M, Ambrosch F, Safary A, D'Hondt E, Delem A. Inactivated hepatitis A vaccine: Long-term antibody persistence. Vaccine 1997; 15:612-5. (Pubitemid 27240473)
33. Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: Indirect evidence of immune memory 12 years after the primary course. J Med Virol 2004; 72:194-6. (Pubitemid 38020545)
34. Van Damme P, Banatvala J, Fay O, et al; International Consensus Group on Hepatitis A Virus Immunity. Hepatitis A booster vaccination: Is there a need? Lancet 2003; 362:1065-71.
35. Werzberger A, Mensch B, Nalin DR, Kuter BJ. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. Vaccine 2002; 20:1699-701. (Pubitemid 34242822)
36. Pasricha N, Datta U, Chawla Y, et al; Immune responses in patients with HIV infection after vaccination with recombinant hepatitis B virus vaccine. BMC Infect Dis 2006; 6:65.
37. Launay O, Grabar S, Gordien E, et al. HEPAVAC Study Group. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008; 49:272-5.
38. Iwarson S, Lindh M, Widerström L. Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 2002; 34:110-1. (Pubitemid 34213371)
39. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat 2006; 13:81-6.
40. Landrum ML, Huppler Hullsiek K, Ganesan A, et al; Hepatitis B vaccine responses in a large United States military cohort of HIV-infected individuals: Another benefit of HAART in those with preserved CD4 count. Vaccine 2009; 27:4731-8.
41. Landrum ML, Huppler Hullsiek K, Ganesan A, et al; Infectious Disease Clinical Research Program HIV Working Group. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2010; 24:545-55.
42. Pigeon JG, Bohidar NR, Zhongxin Z, Wiens BL. Statistical models for predicting the duration of vaccine-induced protection. Drug Inf J 1999; 33:811-9. (Pubitemid 29399776)
43. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. New York: John Wiley & Sons, 2004.